CN1512892A - 口服施用甲状旁腺激素和降钙素 - Google Patents

口服施用甲状旁腺激素和降钙素 Download PDF

Info

Publication number
CN1512892A
CN1512892A CNA028111613A CN02811161A CN1512892A CN 1512892 A CN1512892 A CN 1512892A CN A028111613 A CNA028111613 A CN A028111613A CN 02811161 A CN02811161 A CN 02811161A CN 1512892 A CN1512892 A CN 1512892A
Authority
CN
China
Prior art keywords
pth
calcitonin
effective amount
oral administration
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028111613A
Other languages
English (en)
Chinese (zh)
Inventor
J���¶���
J·奥尔特
M·阿兹里亚
S·D·贝特曼
͵�
J·F·麦克劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1512892(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1512892A publication Critical patent/CN1512892A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028111613A 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素 Pending CN1512892A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
US60/295,169 2001-06-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910258008A Division CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Publications (1)

Publication Number Publication Date
CN1512892A true CN1512892A (zh) 2004-07-14

Family

ID=23136525

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200910258008A Pending CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素
CNA028111613A Pending CN1512892A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200910258008A Pending CN101837120A (zh) 2001-06-01 2002-05-31 口服施用甲状旁腺激素和降钙素

Country Status (25)

Country Link
US (2) US20040186050A1 (enExample)
EP (1) EP1397156B1 (enExample)
JP (2) JP5073153B2 (enExample)
KR (3) KR20040007617A (enExample)
CN (2) CN101837120A (enExample)
AT (1) ATE356631T1 (enExample)
AU (2) AU2002344371B2 (enExample)
BR (1) BRPI0209748B1 (enExample)
CA (1) CA2446929C (enExample)
CO (1) CO5540323A2 (enExample)
CZ (1) CZ307145B6 (enExample)
DE (1) DE60218842T2 (enExample)
EC (1) ECSP034858A (enExample)
ES (1) ES2282436T3 (enExample)
HU (1) HU229613B1 (enExample)
IL (2) IL158777A0 (enExample)
MX (1) MXPA03011027A (enExample)
NO (1) NO330093B1 (enExample)
NZ (1) NZ529439A (enExample)
PL (1) PL211976B1 (enExample)
PT (1) PT1397156E (enExample)
RU (1) RU2300392C2 (enExample)
SK (1) SK287697B6 (enExample)
WO (1) WO2002098453A2 (enExample)
ZA (1) ZA200308625B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
PT1420827E (pt) 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
JP2009508875A (ja) 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
RU2469709C2 (ru) * 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
AU2009283821B2 (en) 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CN104857505A (zh) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형
CN111372586B (zh) 2017-11-20 2023-07-25 诺麦塔制药有限公司 包含chp的骨丢失疾病的预防、改善或治疗用组合物
KR102115353B1 (ko) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
DE69411154T2 (de) * 1993-02-22 1998-10-22 Alza Corp., Palo Alto, Calif. Mittel zur oralen gabe von wirkstoffen
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
DK0993831T3 (da) 1997-02-07 2008-03-25 Emisphere Tech Inc Forbindelser og præparater til tilförsel af aktive stoffer
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (de) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Spritze für medizinische Zwecke
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
AU1189301A (en) 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
NZ529439A (en) 2001-06-01 2005-11-25 Novartis Ag Method for orally administering parathyroid hormone (PTH)
PT1420827E (pt) * 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800564A (zh) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 一种治疗血虚不荣型甲状旁腺功能减退症的中药组合物

Also Published As

Publication number Publication date
AU2002344371B2 (en) 2006-06-29
CA2446929C (en) 2013-04-09
ES2282436T3 (es) 2007-10-16
CN101837120A (zh) 2010-09-22
AU2006225157B2 (en) 2009-04-23
KR20120065429A (ko) 2012-06-20
WO2002098453A2 (en) 2002-12-12
CO5540323A2 (es) 2005-07-29
EP1397156B1 (en) 2007-03-14
NO330093B1 (no) 2011-02-14
DE60218842T2 (de) 2007-12-20
NZ529439A (en) 2005-11-25
CA2446929A1 (en) 2002-12-12
DE60218842D1 (de) 2007-04-26
WO2002098453A3 (en) 2003-07-31
KR20090116836A (ko) 2009-11-11
EP1397156A2 (en) 2004-03-17
US8153587B2 (en) 2012-04-10
BRPI0209748B1 (pt) 2015-11-24
RU2300392C2 (ru) 2007-06-10
PL364089A1 (en) 2004-12-13
CZ307145B6 (cs) 2018-02-07
RU2003136733A (ru) 2005-05-20
SK287697B6 (sk) 2011-06-06
PT1397156E (pt) 2007-05-31
SK14752003A3 (sk) 2004-06-08
HUP0400120A3 (en) 2012-09-28
ZA200308625B (en) 2004-07-13
HU229613B1 (en) 2014-03-28
ATE356631T1 (de) 2007-04-15
PL211976B1 (pl) 2012-07-31
BR0209748A (pt) 2004-07-27
NO20035133D0 (no) 2003-11-18
US20080119411A1 (en) 2008-05-22
IL158777A0 (en) 2004-05-12
JP5073153B2 (ja) 2012-11-14
CZ20033232A3 (cs) 2004-06-16
HUP0400120A2 (hu) 2005-04-28
US20040186050A1 (en) 2004-09-23
KR101320817B1 (ko) 2013-10-21
MXPA03011027A (es) 2004-03-19
NO20035133L (no) 2003-11-18
ECSP034858A (es) 2004-01-28
JP2010189423A (ja) 2010-09-02
IL158777A (en) 2012-06-28
KR20040007617A (ko) 2004-01-24
JP2005500277A (ja) 2005-01-06
AU2006225157A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US8153587B2 (en) Orally administering parathyroid hormone and calcitonin
US9272040B2 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
US8435946B2 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
US20090264368A1 (en) Compositions for delivering parathyroid hormone and calcitonin
AU2002344371A1 (en) Orally administering parathyroid hormone and calcitonin
AU2002333443A1 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination